SCHEMBL647187

SCHEMBL647187

CS(=O)(=O)c1ccccc1CI

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
SLC6A2 P23975 1/20 0.41
CTSB P07858 1/20 0.38
LOX P28300 1/20 0.38
BCAT2 O15382 1/20 0.37
DRD2 P14416 1/20 0.37
ADRA1D P25100 3/20 0.36
MPO P05164 1/20 0.36
NR3C1 P04150 1/20 0.36
ADRA1A P35348 2/20 0.35
P2RX7 Q99572 2/20 0.35
ADRA1B P35368 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2043251 0.84 MEN1 (0.42) MEN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL2024322 0.82 CTSB (0.53) MEN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL30421517 0.78 MYC (0.44) CYP1A2CYP2D6CTSBSMN1; SMN2
SCHEMBL12668238 0.78 CA2 (0.50)
SCHEMBL2376290 0.78 MEN1 (0.41) MEN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL506623 0.78 CYP2D6 (0.45) MEN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL30569427 0.78 CYP2D6 (0.45) MEN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL31532437 0.78 LOX (0.41) MEN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL3412099 0.78 MEN1 (0.44) MEN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL507714 0.78 LOX (0.41) MEN1CYP1A2CYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018081488-A1 HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-03 WO disclosed
EP-1963294-B1 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) NOVARTIS AG (CH) 2012-10-10 EP disclosed
US-8119666-B2 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) NOVARTIS AG (CH) 2012-02-21 US disclosed
US-20080293776-A1 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) NOVARTIS AG (CH) 2008-11-27 US disclosed
EP-1963294-A1 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007067613-A1 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293776-A1 1,2,5-Thiazolidine Derivatives Useful for Treating Conditions Mediated by Protein Tyrosine Phosphatases (Ptpase) PTPRS, PTPN5, PTPRR MEN1 3927/4885CYP1A2 2346/4885CYP3A4 3432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.